What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1432409

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1432409

Europe Autoimmune Disease Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

PAGES: 71 Pages
DELIVERY TIME: 2-3 business days
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

The Europe Autoimmune Disease Diagnostics Market size is estimated at USD 1.38 billion in 2024, and is expected to reach USD 1.82 billion by 2029, growing at a CAGR of 5.69% during the forecast period (2024-2029).

Europe Autoimmune Disease Diagnostics - Market

The major factors driving the market are the increasing prevalence, along with the rising public awareness, technological advancements, and improved laboratory automation.

European countries are being confronted with an increase in the occurrence of the most autoimmune immune disorders. The prevalence rate of multiple sclerosis in Europe is estimated at 83 out of 100,000. Moreover, multiple sclerosis is more common among women than men. In addition, two million people are affected by rheumatoid arthritis and nearly 2-3% of the population is estimated to be affected by psoriasis, which is one of the most common forms of autoimmune diseases. Owing to the aforementioned conditions, early diagnosis and onset of treatment can make a significant difference in preventing permanent damage and disability. Results of autoimmune disease diagnostic tests can confirm a disorder, estimate disease severity, aid in assessing prognosis. They are also useful to follow disease activity.

The increasing awareness of auto-immune diseases, through programs of research, education, support, and advocacy is a key factor augmenting the usage rates. The European Commission is taking several steps to increase awareness among the public regarding the risk factors in developing autoimmune diseases. Thus, as symptoms occur, they can seek diagnosis and begin a treatment regimen.

Europe Autoimmune Disease Diagnostics Market Trends

Rheumatoid Arthritis is Expected to Dominate the Systemic Autoimmune Disease Segment in the Coming Future

Rheumatoid arthritis is a chronic, progressive, and inflammatory autoimmune disease associated with HLA-DR4 and HLA-DR1 serotypes, characterized by persistent inflammation of the synovium that leads to the destruction of joints. The availability of treatment options, such as biologics, increasing awareness about rheumatoid arthritis, and the presence of reimbursement schemes across many countries are driving the growth of the segment. Rheumatoid arthritis (RA) is more prevalent in females. For instance, the United Kingdom has a prevalence rate of 1.2% in females and 0.4% in males.

Increasing incidence of autoimmune diseases, off-label prescription of NSAIDs, and other pain management drugs are expected to increase the demand for RA diagnosis. In addition, extensive focus on the high specificity and sensitivity of RA kits from kit manufacturers, and favorable regulatory guidelines for rapid RA diagnostic kits are expected to fuel the market growth.

Europe Autoimmune Disease Diagnostics Industry Overview

The European autoimmune disease diagnostics market is moderately competitive in nature. Some of the well-known players in the market are Abbott Laboratories, Biomerieux, Bio-rad Laboratories, F. Hoffmann-la Roche, and Thermo Fisher Scientific Inc. However, there are some new companies that are focusing on market penetration, owing to the growing market for autoimmune disease diagnostics in Europe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 49119



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence and Rising Public Awareness
    • 4.2.2 Technological Advancements and Improved Laboratory Automation
  • 4.3 Market Restraints
    • 4.3.1 Slow Turnaround Time of Results and Need of Multiple Diagnostic Test
    • 4.3.2 High Cost
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Disease Type
    • 5.1.1 Systemic Autoimmune Disease
      • Rheumatoid Arthritis
      • Psoriasis
      • Systemic Lupus Erythematosus (SLE)
      • Multiple Sclerosis
      • Other Systemic Autoimmune Diseases
    • 5.1.2 Localized Autoimmune Disease
      • Inflammatory Bowel Disease
      • Type-1 Diabetes
      • Thyroid
      • Other Localized Autoimmune Diseases
  • 5.2 By Diagnostic Technique
    • 5.2.1 Immunofluorescence Assays (IFA)
    • 5.2.2 Enzyme-linked Immunosorbant Assay (ELISA)
    • 5.2.3 Western Blotting
    • 5.2.4 Multiplex Immunoassay
    • 5.2.5 Agglutination
    • 5.2.6 Other Diagnostic Techniques
  • 5.3 Geography
    • 5.3.1 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Biomerieux Inc.
    • 6.1.3 Bio-rad Laboratories
    • 6.1.4 Euroimmun AG
    • 6.1.5 F. Hoffmann-la Roche
    • 6.1.6 Inova Diagnostics Inc.
    • 6.1.7 Myriad Genetics
    • 6.1.8 Siemens Healthineers Inc.
    • 6.1.9 Thermo Fisher Scientific Inc.
    • 6.1.10 Trinity Biotech PLC


Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!